Contact WAO | e-News Sign Up | Site Map | Home  
World Allergy Organization
WAO's mission: To be a global resource and advocate in the field of allergy, advancing excellence in clinical care through education, research and training as a world-wide alliance of allergy and clinical immunology societies.

Medical Journal Reviews

April 2015

Articles are selected for their importance to clinicians who care for patients with asthma and allergic/immunologic diseases by Juan Carlos Ivancevich, MD, WAO Web Editor-in-Chief, and John J. Oppenheimer, MD - FACAAI - FAAAAI, WAO Reviews Editor.

1. Use of modern antidepressant during pregnancy do not increase the risk of asthma.

Liu X, Olsen J, Pedersen LH, Agerbo E, Yuan W, and L J. Antidepressant Use During Pregnancy and Asthma in the Offspring. Pediatrics 2015, 9 March. (doi: 10.1542/peds.2014-4073)

Full Text, Free

Editor’s comment:
In this prospective cohort study, the authors found that maternal antidepressant use during pregnancy generally did not increase the risk of asthma except for use of older antidepressants, which could reflect confounding by the severity of maternal depression.

2. Best available evidence on how to monitor children with asthma.

Pijnenburg MW, Baraldi E, Brand PLP, Carlsen KH, Eber E et al.  Monitoring asthma in children. European Respiratory Journal 2015; 45(4): 906 – 925. (doi:10.1183/09031936.00088814)

Abstract

Editor’s comment:
This ERS statement summarizes the literature regarding monitoring children with asthma, reviewing available tools, such as clinical measures (ie. ACT, ACQ etc), lung function, bronchial responsiveness and inflammatory markers in children with asthma. Management-related issues, comorbidities and environmental factors are also reviewed.

3. Current and future use of biological agents for the treatment of asthma.

Darveaux J and Busse WW. Biologics in Asthma—The Next Step Toward Personalized Treatment. The Journal of Allergy and Clinical Immunology 2015; 3(2): 152 – 160. (doi:http://dx.doi.org/10.1016/j.jaip.2014.09.014)

Abstract

Editor’s comment:
The authors identify future and current treatment options for patients with asthma who are suboptimally controlled. They describe how patient endotypes may direct selection of specific monoclonal antibody therapy being developed for the treatment of asthma.

4. Hypothesis: Bystander clinical effect of allergen immunotherapy in poly-allergic patients.

Ciprandi G. Clinical bystander effect exerted by allergen immunotherapy: a hypothesis. European Annals of Allergy and Clinical Immunology 2015; 47(2); 62 -63.

Full Text, Free

Editor’s comment:
This case report shows that a poly-allergic patient, successfully treated with immunotherapy to Parietaria, also achieved a clinical tolerance towards other causal allergens, such as mites and cat. From this anecdote the author proposes the hypothesis that a bystander clinical effect may be observed during allergen immunotherapy in poly-allergic patients.  This gives credence to the approach of SLIT with a single dominant allergen.  Certainly, further prospective study is needed to resolve this issue.

5. Improving the classification and coding of hypersensitivity/allergic diseases.

Tanno LK, Calderon MA, Goldberg BJ, Gayraud J, Bircher AJ et al. Constructing a classification of hypersensitivity/allergic diseases for ICD-11 by crowdsourcing the allergist community. European Journal of Allergy and Clinical Immunology, published online before print 17 March 2015. (doi:10.1111/all.12604)

Abstract

Editor’s comment:
An international expert panel review the classification of hypersensitivity/allergic diseases and validate it for the International Classification of Diseases (ICD-11) by crowdsourcing the allergist community to construct a high-level complex structure of classification for hypersensitivity/allergic diseases.